PYXS
HEALTHCAREPyxis Oncology Inc
AI Insight
What's Moving PYXS Today?
No stock-specific AI insight has been generated for PYXS yet. Check back soon — insights are generated from recent news analysis.
Market Briefings featuring PYXS
52-Week Range
$0.97$5.55
$2.19
Fundamentals
Market Cap$129M
P/E Ratio—
EPS$-1.30
Dividend Yield—
Dividend / Share—
ROE-121.7%
Profit Margin—
Debt / Equity—
Trading
Volume285K
Avg Volume (10D)—
Shares Outstanding63.4M
PYXS News
21 articles- Analysts See Nearly 3X Upside in Pyxis Oncology (PYXS)Yahoo! Finance Canada·Jun 10, 2026
- PYXS: Mid-year data will clarify MICVO's efficacy, safety, and pivotal trial path in head and neck cancerTradingView·Jun 4, 2026
- Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical MilestonesYahoo Finance·May 14, 2026
- Pyxis Oncology to Participate in Upcoming Investor ConferencesYahoo Finance·May 13, 2026
- Creative Global Technology Holdings And 2 Other Promising Penny StocksYahoo Finance·May 12, 2026
- Pyxis Oncology Appoints Nelson Azoulay as Chief Business OfficerYahoo Finance·May 7, 2026
- NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDAYahoo Finance·May 6, 2026
- Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026Yahoo Finance·Apr 17, 2026
- 3 Penny Stocks With Market Caps Under $400M To ConsiderYahoo Finance·Apr 13, 2026
- Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 23, 2026
- 3 Penny Stocks With Market Caps Over $50M To WatchYahoo Finance·Feb 6, 2026
- Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program ContinuityYahoo Finance·Feb 3, 2026
- 3 Promising Penny Stocks With Market Caps Up To $300MYahoo Finance·Jan 7, 2026
- Wall Street Set to Open Higher Thursday as Inflation Rises Less Than Expected; Jobless Claims DeclineYahoo Finance·Dec 18, 2025
- Investors Await Key Inflation, Employment Data as US Futures Rise Thursday Pre-BellYahoo Finance·Dec 18, 2025
- Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaYahoo Finance·Dec 18, 2025
- 3 Promising Penny Stocks With Over $90M Market CapYahoo Finance·Dec 9, 2025
- Pyxis Oncology And 2 Other Promising Penny Stocks To WatchYahoo Finance·Nov 4, 2025
- Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 3, 2025
- Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus TherapeuticsYahoo Finance·Oct 15, 2025
- Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should KnowYahoo Finance·Oct 14, 2025
All 21 articles loaded
Price Data
Open$2.08
Previous Close$2.13
Day High$2.26
Day Low$2.07
52 Week High$5.55
52 Week Low$0.97
52-Week Range
$0.97$5.55
$2.19
Fundamentals
Market Cap$129M
P/E Ratio—
EPS$-1.30
Dividend Yield—
Dividend / Share—
ROE-121.7%
Profit Margin—
Debt / Equity—
Trading
Volume285K
Avg Volume (10D)—
Shares Outstanding63.4M
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating cancers. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—